BACKGROUND: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. PATIENTS AND METHODS: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. RESULTS: Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first cycle of the retreatment was 6 months. Overall response rate was 53.8\% with 19 partial responses (48.7\%) and 2 complete responses (5.1\%). Disease stabilization was obtained in 35.9\% of patients and progression in four patients (10.2\%). Median progression-free survival was 6.6 months. The correlation between skin toxicity during first cetuximab therapy and during cetuximab rechallenge was significant (P = 0.01). CONCLUSION: Rechallenge with the same cetuximab-based therapy may achieve a new important clinical benefit further delaying the progression of disease and improving the therapeutic options.
|Data di pubblicazione:||2012|
|Titolo:||Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?|
|Autori:||D. Santini; B. Vincenzi; R. Addeo; C. Garufi; G. Masi; M. Scartozzi; A. Mancuso; A. M. Frezza; O. Venditti; M. Imperatori; G. Schiavon; G. Bronte; G. Cicero; F. Recine; E. Maiello; S. Cascinu; A. Russo; A. Falcone; G. Tonini|
|Digital Object Identifier (DOI):||10.1093/annonc/mdr623|
|Appare nelle tipologie:||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris